Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the infectious etiologic agent associated with Kaposi’s sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. It has been shown that high KSHV prevalence and high incidence of both classic KS and AIDSassociated KS are found mostly among people of Uygur ethnicity in Xinjiang, while people of Han ethnicity in Xinjiang have a higher KSHV seroprevalence than those of other Han populations in mainland China. However, it is still unclear why there is such geographical and population variation in KSHV distribution in China. In this work, we focused on the populations in the Kashgar region and Urumqi area, where a total of 1294 research subjects were randomly selected to investigate the potential correlation between KSHV prevalence and different ethnicities in endemic areas of Xinjiang, and to determine risk factors that may affect KSHV infection rates or KS incidence. We identified a high seroprevalence of KSHV and high peripheral blood DNA infection in the general Uygur and Han populations in both Urumqi and Kashgar regions of Xinjiang, and determined that advancing age, low education level, and stationary population status affect KSHV infection rates. Further, KSHV-positive Uygur participants were shown to have higher prevalence of neutralizing antibodies and neutralizing antibody titers than KSHV-positive Han participants.
References
Ablashi DV, Chatlynne LG, Whitman JE, Jr., Cesarman E 2002. Spectrum of Kaposi’s sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev, 15: 439–464.
Baillargeon J, Deng JH, Hettler E, Harrison C, Grady JJ, Korte LG, Alexander J, Montalvo E, Jenson HB, Gao SJ. 2001. Seroprevalence of Kaposi’s sarcoma-associated herpesvirus infection among blood donors from Texas. Ann Epidemiol, 11: 512–518.
Bélec L, Cancré N, Hallouin MC, Morvan J, Si Mohamed A, Grésenguet G. 1998. High prevalence in Central Africa of blood donors who are potentially infectious for human herpesvirus 8. Transfusion, 38: 771–775.
Bigoni B, Dolcetti R, de Lellis L, Carbone A, Boiocchi M, Cassai E, Di Luca D. 1996. Human herpesvirus 8 is present in the lymphoid system of healthy persons and can reactivate in the course of AIDS. J Infect Dis, 173: 542–549.
Boshoff C, Weiss RA. 2001. Epidemiology and pathogenesis of Kaposi’s sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci, 356: 517–534.
Bower M, Palmieri C, Dhillon T. 2006. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis, 19: 14–19.
Brown EE, Whitby D, Vitale F, Fei PC, Del Carpio C, Marshall V, Alberg AJ, Serraino D, Messina A, Gafa L, Goedert JJ. 2005. Correlates of human herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma. Int J Epidemiol, 34: 1110–1117.
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med, 332: 1186–1191.
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 1994. Identification of herpesvirus -like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science, 266: 1865–1869.
Cook-Mozaffari P, Newton R, Beral V, Burkitt DP. 1998. The geographical distribution of Kaposi’s sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer, 78: 1521–1528.
Dedicoat M, Newton R. 2003. Review of the distribution of Kaposi’s sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi’s sarcoma. Br J Cancer, 88: 1–3.
Dilnur P, Katano H, Wang ZH, Osakabe Y, Kudo M, Sata T, Ebihara Y. 2001. Classic type of Kaposi’s sarcoma and human herpesvirus 8 infection in Xinjiang, China. Pathol Int, 51: 845–852.
Du W, Chen G, Sun H. 2000. Antibody to human herpesvirus type 8 in the general populations of Xinjiang Autonomous Region. Chinese J Exp Clin Virol, 14: 44–46.
Enbom M, Urassa W, Massambu C Thorstensson R, Mhalu F, Linde A. 2002. Detection of human herpesvirus 8 DNA in serum from blood donors with HHV-8 antibodies indicates possible bloodborne virus transmission. J Med Virol, 68: 264–267.
Fu B, Sun F, Li B, Yang L, Zeng Y, Sun X, Xu F, Rayner S, Guadalupe M, Gao SJ, Wang L. 2009. Seroprevalence of Kaposi’s sarcoma-associated herpesvirus and risk factors in Xinjiang, China. J Med Virol, 81: 1422–1431.
Fujii T, Taguchi H, Katano H, Mori S, Nakamura T, Nojiri N, Nakajima K, Tadokoro K, Juji T, Iwamoto A. 1999. Seroprevalence of human herpesvirus 8 in human immunodeficiency virus 1-positive and human immunodeficiency virus 1-negative populations in Japan. J Med Virol, 57: 159–162.
He F, Wang X, He B, Feng Z, Lu X, Zhang Y, Zhao S, Lin R, Hui Y, Bao Y, Zhang Z, Wen H. 2007. Human herpesvirus 8: serovprevalence and correlates in tumor patients from Xinjiang, China. J Med Virol, 79: 161–166.
Kimball LE, Casper C, Koelle DM, Morrow R, Corey L, Vieira J. 2004. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis, 189: 2016–2022.
Liu Z, Fang Q, Zhou S, Minhas V, Wood C, He N, Zhang T. 2017. Seroprevalence of Kaposi’s sarcoma-associated herpesvirus among HIV-infected Uygurs in Xinjiang, China. J Med Virol, 89: 1629–1635.
Minhas V, Crabtree KL, Chao A, M’soka TJ, Kankasa C, Bulterys M, Mitchell CD, Wood C. 2008. Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. Am J Epidemiol, 168: 311–320.
Minhas V, Crosby LN, Crabtree KL, Phiri S, M’soka TJ, Kankasa C, Harrington WJ, Mitchell CD, Wood C. 2008. Development of an immunofluorescence assay using recombinant proteins expressed in insect cells to screen and confirm presence of human herpesvirus 8-specific antibodies. Clin Vaccine Immunol, 15: 1259–1264.
Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D.; Babinet P, d’Agay MF, Clauvel JP, Raphael M, Degos L 1995. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood, 86: 1276–1280.
Vitale F, Viviano E, Perna AM, Bonura F, Mazzola G, Ajello F, Romano N. 2000. Serological and virological evidence of nonsexual transmission of human herpesvirus type 8 (HHV-8). Epidemiol Infect, 125: 671–675.
Wang G, Zhao Y, Chen H. 2002. Detection of human herpesvirus 8 in healthy blood donors in Northeast China. Chinese Journal of dermatology, 17: 15–18.
Wang H, Liu J, Dilimulati, Li L, Ren Z, Wen H, Wang X. 2011. Seroprevalence and risk factors of Kaposi’s sarcoma-associated herpesvirus infection among the general Uygur population from south and north region of Xinjiang, China. Virol J, 8: 539.
Wang X, He B, Zhang Z, Liu T, Wang H, Li X, Zhang Q, Lan K, Lu X, Wen H. 2010. Human herpesvirus-8 in northwestern China: epidemiology and characterization among blood donors. Virology Journal, 7: 62–69.
Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett, FE, Aldam DM, Denton AS. 1995. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet, 346: 799–802.
Yoshida M, Torigoe S, Ikeue K, Yamada M. 2002. Neutralizing antibody responses to human herpesviruses 6 and 7 do not cross-react with each other, and maternal neutralizing antibodies contribute to sequential infection with these viruses in childhood. Clin Diagn Lab Immunol, 9: 388–393.
Zavitsanou A, Malliori M, Sypsa V, Petrodaskalaki M, Psichogiou M, Rokka C, Giannopoulos A, Kalapothaki V, Whitby D, Hatzakis A. 2010. Seroepidemiology of human herpesvirus 8 (HHV-8) infection in injecting drug users. Epidemiol Infect, 138: 403–408.
Zavitsanou A, Sypsa V, Petrodaskalaki M, Kalapothaki V, Whitby D, Hatzakis A. 2007. Human herpesvirus 8 (HHV-8) infection in healthy urban employees from Greece: seroprevalence and associated factors. J Med Virol, 79: 591–596.
Acknowledgments
This study was supported by research grants from the National Natural Science Foundation of China (U1603117; 81560473; 81560442), Doctoral Foundation and Technology Research and Achievements Transformation Program of Xinjiang production and Construction Corps (2014BB021; 2015AD003), the United States National Institutes of Health Fogarty International Center (D43 TW001492), NCI (CA75903) and NCRR COBRE (RR15635) to C. Wood; Y. Zeng was a Fogarty Scholar.
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
12250_2017_4049_MOESM1_ESM.pdf
Prevalence of Kaposi’s sarcoma-associated herpesvirus in Uygur and Han populations from the Urumqi and Kashgar regions of Xinjiang, China
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Zheng, J., Yang, Y., Cui, M. et al. Prevalence of Kaposi’s sarcoma-associated herpesvirus in Uygur and Han populations from the Urumqi and Kashgar regions of Xinjiang, China. Virol. Sin. 32, 396–403 (2017). https://doi.org/10.1007/s12250-017-4049-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-017-4049-9
Keywords
- Kaposi’s sarcoma associated herpesvirus (KSHV)
- prevalence
- Uygur ethnicity
- Han ethnicity
- Xinjiang